Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2001

View Archived Issues

GlaxoSmithKline updates R&D activities --merger makes way for robust pipeline

NIH licensing opportunity: simian-human HAV chimeras

NIH licensing opportunity: novel antimalarial naphthylisoquinoline alkaloid compounds

Method of producing water-soluble aminoflavone analogues available for licensing from NIH

St. Jude and GlaxoSmithKline awarded grant for multidrug-resistant tuberculosis research

Maxygen and IAVI to develop novel AIDS vaccines

Positive quality-of-life and survival results reported for Maxim's Ceplene

BioMarin reports product development update

2000 achievements at Corixa discussed

U.S. researchers design chaperone-binding antifibrillogenic peptide

Inhibition of caspase 2 or 3 may be beneficial in cerebral vasospasm following SAH

FDA Antiviral Drugs Advisory Committee recommends approval of Roche's valganciclovir

Interneuron's PRO-2000 to enter phase II/III NIH-supported HIV prevention trial

FDA grants approval for Reminyl as treatment of Alzheimer's disease

SeMet induces cell cycle alterations, growth inhibition and apoptosis in colon cancer cells

BACE1-deficient mice exhibit normal phenotype although beta-amyloid generation is abolished

InKine cleared to proceed with Colirest pivotal trial for treatment of Crohn's disease

Neurotrophic agents emerge en masse from Vertex pipeline

Kaneka isolates and synthesizes new steroid glycosides with antitumor activity

Selective Y5 receptor antagonists identified in Synaptic/Novartis collaboration

Japanese patent issued to Santen for new agents for glaucoma

Endothelial function improved by ETA antagonist in CHF patients

NeoPharm's CRADA agreement for IL-13 receptor research extended